BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 33491830)

  • 21. Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT.
    Evangelista L; Cervino AR; Michieletto S; Saibene T; Orvieto E; Bozza F; Ghiotto C
    Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):205-215. PubMed ID: 25501326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting neo-adjuvant chemotherapy response and progression-free survival of locally advanced breast cancer using textural features of intratumoral heterogeneity on F-18 FDG PET/CT and diffusion-weighted MR imaging.
    Yoon HJ; Kim Y; Chung J; Kim BS
    Breast J; 2019 May; 25(3):373-380. PubMed ID: 29602210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PET/CT with
    Teixeira SC; Koolen BB; Elkhuizen PH; Vrancken Peeters MT; Stokkel MP; Rodenhuis S; van der Noort V; Rutgers EJ; Valdés Olmos RA
    Eur J Surg Oncol; 2017 Apr; 43(4):625-635. PubMed ID: 27847287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidental mediastinal dose does not explain low mediastinal node recurrence rates in patients with early-stage NSCLC treated with stereotactic body radiotherapy.
    Rwigema JC; Chen AM; Wang PC; Lee JM; Garon E; Lee P
    Clin Lung Cancer; 2014 Jul; 15(4):287-93. PubMed ID: 24594401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patients' experiences with decisions on timing of chemotherapy for breast cancer.
    de Ligt KM; Spronk PER; van Bommel ACM; Vrancken Peeters MTFD; Siesling S; Smorenburg CH;
    Breast; 2018 Feb; 37():99-106. PubMed ID: 29128583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies.
    Sheikhbahaei S; Trahan TJ; Xiao J; Taghipour M; Mena E; Connolly RM; Subramaniam RM
    Oncologist; 2016 Aug; 21(8):931-9. PubMed ID: 27401897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incorporation of Treatment Response, Tumor Grade and Receptor Status Improves Staging Quality in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Bergquist JR; Murphy BL; Storlie CB; Habermann EB; Boughey JC
    Ann Surg Oncol; 2017 Nov; 24(12):3510-3517. PubMed ID: 28828583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of
    Akimoto E; Kadoya T; Kajitani K; Emi A; Shigematsu H; Ohara M; Masumoto N; Okada M
    Clin Breast Cancer; 2018 Feb; 18(1):45-52. PubMed ID: 28993056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer.
    Hieken TJ; Boughey JC; Jones KN; Shah SS; Glazebrook KN
    Ann Surg Oncol; 2013 Oct; 20(10):3199-204. PubMed ID: 23846781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early response to neo-adjuvant chemotherapy in carcinoma of the breast predicts both successful breast-conserving surgery and decreased risk of ipsilateral breast tumor recurrence.
    Ishitobi M; Komoike Y; Motomura K; Koyama H; Inaji H
    Breast J; 2010; 16(1):9-13. PubMed ID: 19929889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Restaging the axilla after neo-adjuvant chemotherapy for breast cancer: Predictive factors for residual metastatic lymph node disease with negative imaging findings.
    Jung N; Kim HJ; Jung JH; Lee SW; Chae YS; Cheon H; Lee SM; Kim WH
    Breast J; 2019 Mar; 25(2):196-201. PubMed ID: 30714256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore.
    Steenbruggen TG; van Seijen M; Janssen LM; van Ramshorst MS; van Werkhoven E; Vrancken Peeters MTDF; Wesseling J; Lips EH; Sonke GS
    Clin Cancer Res; 2019 Aug; 25(16):4985-4992. PubMed ID: 31076546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in the findings of dynamic MRI by preoperative CAF chemotherapy for patients with breast cancer of stage II and III: pathologic correlation.
    Tsuboi N; Ogawa Y; Inomata T; Yoshida D; Yoshida S; Moriki T; Kumon M
    Oncol Rep; 1999; 6(4):727-32. PubMed ID: 10373646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Staging and Response Evaluation to Neo-Adjuvant Chemoradiation in Esophageal Cancers Using 18FDG PET/ CT with Standardized Protocol.
    Fatima N; Zaman MU; Zaman A; Zaman U; Tahseen R; Zaman S
    Asian Pac J Cancer Prev; 2019 Jul; 20(7):2003-2008. PubMed ID: 31350957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The value of pre- and post-neoadjuvant chemotherapy F-18 FDG PET/CT scans in breast cancer: comparison with MRI.
    Choi EK; Yoo IR; Kim SH; Park SY; O JH; Kang BJ
    Acta Radiol; 2018 Jan; 59(1):41-49. PubMed ID: 28427271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.
    Keam B; Im SA; Koh Y; Han SW; Oh DY; Cho N; Kim JH; Han W; Kang KW; Moon WK; Kim TY; Park IA; Noh DY; Chung JK; Bang YJ
    Breast Cancer; 2013 Apr; 20(2):167-73. PubMed ID: 22311581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical significance of incidental finding of focal activity in the breast at 18F-FDG PET/CT.
    Kang BJ; Lee JH; Yoo IeR; Kim SH; Choi JJ; Jeong SH; Yim HW
    AJR Am J Roentgenol; 2011 Aug; 197(2):341-7. PubMed ID: 21785079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDG-PET/CT in high-risk primary breast cancer-a prospective study of stage migration and clinical impact.
    Vogsen M; Jensen JD; Christensen IY; Gerke O; Jylling AMB; Larsen LB; Braad PE; Søe KL; Bille C; Ewertz M; Hildebrandt MG
    Breast Cancer Res Treat; 2021 Jan; 185(1):145-153. PubMed ID: 32920740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The value of 18F-FDG PET/CT imaging in breast cancer staging.
    Yararbas U; Avci NC; Yeniay L; Argon AM
    Bosn J Basic Med Sci; 2018 Feb; 18(1):72-79. PubMed ID: 28763628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.